Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.59 |
| ▸ | CDK2 | P24941 | 13/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK7 | P50613 | 1/20 | 0.36 |
| ▸ | CCNH | P51946 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953833 | 0.92 | GSK3B (0.58) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13305343 | 0.89 | GSK3B (0.45) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL12953741 | 0.81 | GSK3B (0.41) | GSK3BCDK2CCNE1 | |
| SCHEMBL12952999 | 0.78 | GSK3B (0.68) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL12953472 | 0.78 | GSK3B (0.70) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13116953 | 0.76 | GSK3B (0.67) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL13305345 | 0.76 | GSK3B (0.59) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL12953010 | 0.75 | GSK3B (0.63) | GSK3BCDK2CCNE1CHEK1CCNA2 | |
| SCHEMBL12952914 | 0.74 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL14545214 | 0.74 | GSK3B (0.64) | GSK3BCDK2CCNE1CHEK1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |